Novartis Finland

What Novartis Finland does

Novartis Finland Oy is the Finnish operating subsidiary of global pharmaceutical company Novartis AG, headquartered in Espoo with approximately 55 employees. The entity functions as a local market-access and commercial arm rather than an independent drug developer: it distributes and supports Novartis's prescription pharmaceutical portfolio across therapeutic areas including oncology, immunology, neurology, cardiovascular, and hematology within the Finnish healthcare system. Its go-to-market is sales-led, combining field sales representatives targeting physicians and hospital pharmacists with digital channels such as the NovartisPro professional portal and the Medhub medical-information platform.

The company's offerings extend beyond product supply into healthcare professional services, including clinical trial participation programs and the Sydänohjelma Polku cardiovascular care-pathway initiative aimed at coordinated heart-patient care. A patient-facing health information portal covers a broad set of disease areas, and the subsidiary maintains ongoing collaborations with patient organizations to support education and advocacy. Revenue is generated through prescription pharmaceutical sales distributed via Finnish pharmacies and healthcare institutions, with pricing and reimbursement governed by the Finnish Medicines Agency (Fimea) and the Social Insurance Institution (Kela). Novartis Finland operates as a wholly-owned subsidiary of Novartis AG, a publicly traded company listed on the New York Stock Exchange, and relies on the parent group's R&D pipeline, regulatory approvals, and global scale for its competitive position.

Name

Novartis Finland

Legal name

Novartis Finland Oy

Website

https://novartis.fi

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Prescription pharmaceuticals
• Oncology treatments
• Cardiovascular medicines
• Clinical research services
• Patient support programs

Headquarters

HQ city

Finland

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

1. Pharmaceutical Product Sales: Novartis Finland generates revenue through the sale of prescription pharmaceutical products including medicines for oncology, immunology, neurology, cardiovascular diseases, and other therapeutic areas. Products are distributed to healthcare providers and patients through pharmacies and healthcare institutions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Novartis Finland Oy markets and distributes prescription pharmaceutical products from its global parent Novartis AG across multiple therapeutic areas, including oncology, immunology, neurology, cardiovascular diseases, and hematology. The subsidiary also offers clinical research participation services, a healthcare-professional portal (NovartisPro), the Sydänohjelma Polku cardiovascular care program, and a patient-facing health information portal covering a broad range of conditions.

Product overview

Novartis Finland operates as a subsidiary of the global pharmaceutical company Novartis, offering a portfolio of medicines and healthcare solutions. The company provides NovartisPro, a dedicated platform for healthcare professionals, alongside clinical trial participation services and the Sydänohjelma Polku (Heart Path Program) for cardiovascular patient care. Patient-facing services include a comprehensive health information portal covering therapeutic areas such as oncology, immunology, neurology, cardiology, and hematology. The company focuses on developing innovative treatments for diseases with high patient need, with significant investments in research and development supporting its product portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• NovartisPro A dedicated platform for Finnish healthcare professionals providing access to product information, medical resources, professional development materials, and clinical tools for Novartis medicines.
• Sydänohjelma Polku (Heart Path Program) A cardiovascular care program aimed at providing equitable health outcomes for heart patients in Finland through coordinated care pathways and clinical decision support.
• Kliiniset tutkimukset (Clinical Trials) Clinical research services enabling Finnish healthcare professionals and sites to participate in Novartis-sponsored clinical studies across multiple therapeutic areas.
• Patient Health Information Portal Patient-facing information portal covering multiple therapeutic areas including axial spondylarthritis, atherosclerosis, hematology, hidradenitis suppurativa, immune thrombocytopenia, migraine, multiple sclerosis, myelofibrosis, myeloproliferative diseases, psoriatic arthritis, polycythemia vera, psoriasis, breast cancer, heart failure, and urticaria, aimed at Finnish patients and families.

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Patient organizationscoreStrategic or Co-development PartnerNovartis collaborates with patient organizations around the world to find new ways to improve and extend people's lives. These partnerships support patient support programs, health education, and advocacy initiatives.

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

Direct peers

• GSK Finland: GSK's Finnish subsidiary selling specialty and primary-care pharmaceuticals, including vaccines, HIV, and oncology. Comparable multinational pharma local-sales entity operating under the same Kela/Fimea reimbursement framework.
• Pfizer Finland: Pfizer's Finnish subsidiary, selling branded prescription pharmaceuticals across oncology, vaccines, and specialty care via field sales and HCP portals. Directly comparable in business model, therapeutic breadth, and operating footprint within Finland.
• Bayer Finland: Bayer's Finnish subsidiary covering pharmaceuticals (cardiology, women's health, oncology) and crop science. Comparable as a multinational pharma subsidiary with field-sales and HCP engagement in Finland.
• MSD Finland (Merck & Co.): MSD's Finnish arm selling branded pharmaceuticals in oncology, vaccines, and specialty care. Highly comparable as a multinational pharma subsidiary operating a similar field-sales and HCP-engagement model in Finland.
• Sanofi Finland: Sanofi's Finnish subsidiary distributing specialty pharmaceuticals in immunology (Dupixent), rare diseases, and vaccines. Comparable business model as a multinational pharma local sales entity.
• AstraZeneca Finland: AstraZeneca's Finnish subsidiary with a strong oncology, cardiovascular, renal, and respiratory specialty pharma portfolio. Comparable in therapeutic breadth, GTM, and reliance on Kela reimbursement.
• Roche Finland: Roche's Finnish subsidiary focused on oncology, hematology, immunology, and neurology specialty pharmaceuticals, distributed via field sales to HCPs and pharmacies. Comparable in therapeutic mix and specialty-pharma GTM motion in Finland.
• AbbVie Finland: AbbVie's Finnish subsidiary focused on specialty pharma in immunology (Humira/Skyrizi/Rinvoq), oncology, and neuroscience. Directly comparable as a specialty-pharma-led multinational subsidiary operating in Finland.
• Eli Lilly Finland: Eli Lilly's Finnish subsidiary selling specialty pharmaceuticals in oncology, diabetes, immunology, and neuroscience. Comparable in business model and specialty-pharma positioning within the Finnish market.

Regional players

• Oriola: One of Finland's leading pharmaceutical wholesalers and distributors, partnering with multinational pharma companies (including Novartis) to distribute products through pharmacies. Comparable as a Finland-specific pharma distribution intermediary, though operating at a different layer of the value chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/novartis-finland

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novartis Finland